What is the clinical evidence from this study?

Study design: Cohort. Population: Hypertriglyceridemia (n=936). Intervention: Asymmetric dimethylguanidino valeric acid (ADGV) vs. Lower ADGV levels. Primary outcome: Incident hypertriglyceridemia (HTG) (HR 1.87, 95% CI 1.16-3.02, p=0.018).

What question did this study set out to answer?

Examine the relationship between asymmetric dimethylguanidino valeric acid (ADGV) and hypertriglyceridemia.

March 9, 2026Metabolomics0 citationsOpen Access

Asymmetric dimethylguanidino valeric acid as an independently associated risk factor for early hypertriglyceridemia and dyslipidemia

YHYueyuan HanUniversity of Liverpool QXQianling XiongSun Yat-sen University JWJiahui WangUniversity of Liverpool

Key Result

Higher circulating ADGV levels were independently associated with an increased risk of incident hypertriglyceridemia, with a hazard ratio of 1.87 per standard deviation increase.

Key Points

Examine the relationship between asymmetric dimethylguanidino valeric acid (ADGV) and hypertriglyceridemia.
Cross-sectional cohort analysis to assess prevalent hypertriglyceridemia.
Independent prospective cohort analysis for incident hypertriglyceridemia.
Hepatocyte experiments to examine ADGV's role in liver fat production.
ADGV levels were significantly higher in individuals with hypertriglyceridemia.
ADGV was found to be an independent risk factor for developing hypertriglyceridemia over time.
Experimental results indicated that ADGV promotes lipid production in liver cells.

Study Design

Type

Cohort (n=936)

Multicenter

Yes

Structured PICO

Is elevated circulating ADGV associated with an increased risk of prevalent and incident hypertriglyceridemia?

Population

936 adults aged 30 to 65 years from two independent Chinese cohorts, evaluated for the association between circulating ADGV levels and prevalent or incident hypertriglyceridemia over a median follow-up of 1.8 years.

Exposure

Elevated circulating asymmetric dimethylguanidino valeric acid (ADGV) levels (observational) and ADGV intervention in hepatocytes

Comparator

Lower circulating ADGV levels / normal triglyceride levels

Outcome

Prevalent and incident hypertriglyceridemia (fasting TG ≥ 1.7 mmol/L)surrogate

Higher circulating ADGV is independently associated with prevalent and incident hypertriglyceridemia, suggesting it may serve as a biomarker and contributory factor in early dyslipidemia and hepatic lipogenesis.

Main Result

Hazard Ratio: 1.87 (95% CI 1.16–3.02)

p-value: p=0.018

Limitations

Did not directly assess inflammatory pathways or include dedicated inflammatory biomarkers.
Follow-up was relatively short and the number of incident HTG events was modest.
Did not measure the stereoisomer SDGV in parallel, precluding assessment of isomer specificity.
Both cohorts comprised Chinese participants, limiting the generalizability of the findings to other ancestries.

Abstract

Higher circulating ADGV was independently associated with prevalent and incident hypertriglyceridemia across a cross-sectional cohort and an independent prospective cohort, and hepatocyte experiments support a contributory role of ADGV in hepatic lipogenesis.

AI에게 질문

Bookmark

View Full Paper